Latest Licensing Agreements News

Algorae Pharmaceuticals has struck an exclusive commercial and licensing agreement with global pharma Zydus Lifesciences to bring 10 injectable, oral, and specialty medicines to Australia and New Zealand, pending regulatory approvals.

Singular Health has received a US$500,000 payment from Provider Network Solutions following the deployment of an additional 500 3DICOM MD® licenses, marking progress in commercial adoption and cost-saving benefits within a major US healthcare network.

Marquee Resources has entered a 24-month patent license and option agreement with UT-Battelle LLC, granting access to advanced rare earth element separation technologies from Oak Ridge National Laboratory. This positions Marquee to explore downstream processing opportunities for its Redlings REE Project in Western Australia.

Wellnex Life has extended its licensing and supply agreement with Haleon UK for soft gel liquid paracetamol products until March 2027, reinforcing its position in the global analgesics market.

NeuRizer Ltd has advanced its NeuRizer Urea Project with key environmental approvals and construction plans, while raising $350,000 through private placements. However, the company faces a trading suspension as it works to resolve audit and compliance issues with the ASX.

St George Mining has partnered with Spain’s Tecnicas Reunidas to test advanced processing technology on its Araxá rare earths, aiming to unlock European markets alongside existing US and Brazilian alliances.

BrainChip Holdings has inked a global licensing agreement with Korea’s EDGEAI, granting access to its Akida 2 neuromorphic AI technology for EDGEAI’s upcoming semiconductor products. The deal includes milestone payments and royalties, marking a significant step in BrainChip’s global expansion and the growing edge AI market.

Temas Resources has formed a Scientific Advisory Board of hydrometallurgical leaders to accelerate the rollout of its innovative Regenerative Chloride Leaching technology, promising major cost and environmental benefits in critical minerals processing.

Weebit Nano has launched a significant A$80 million institutional placement, alongside additional funding initiatives, to accelerate its ReRAM technology leadership and broaden AI-related offerings.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

PARKD Limited reported a 37% revenue decline to $3.88 million for H1 FY2026, driven by the winding down of its flagship Audi Centre Myaree project. The company posted a $1.03 million loss as it invests in East Coast growth and commissions a new prefabrication facility in Penrith, NSW.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.